OTCMKTS:ELOX - Eloxx Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $15.91 -0.13 (-0.81 %) (As of 09/24/2018 04:00 PM ET)Previous Close$16.04Today's Range$15.55 - $16.1052-Week Range$3.90 - $24.60Volume54,200 shsAverage Volume93,424 shsMarket Capitalization$313.82 millionP/E RatioN/ADividend YieldN/ABeta1.25 Company ProfileDiscussionAnalyst RatingsChartEarnings HistoryInsider TradesHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel therapeutics for the treatment of rare and ultra-rare premature stop codon diseases. Its lead program is ELX-02, which is in Phase I clinical trial, which focuses on the treatment of cystic fibrosis and cystinosis patients with diagnosed nonsense mutations. The company was founded in 2013 and is headquartered in Waltham, Massachusetts. Receive ELOX News and Ratings via Email Sign-up to receive the latest news and ratings for ELOX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Commercial physical research Sub-IndustryN/A SectorMedical SymbolOTCMKTS:ELOX CUSIPN/A Webwww.eloxxpharma.com Phone858-909-0749 Debt Debt-to-Equity RatioN/A Current Ratio7.16 Quick Ratio7.16 Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$80,000.00 Price / Sales6,932.78 Cash FlowN/A Price / CashN/A Book Value$0.78 per share Price / Book20.40 Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-21,210,000.00 Net MarginsN/A Return on Equity-248.30% Return on Assets-162.16% Miscellaneous Employees15 Outstanding Shares34,860,000Market Cap$313.82 million Eloxx Pharmaceuticals (OTCMKTS:ELOX) Frequently Asked Questions What is Eloxx Pharmaceuticals' stock symbol? Eloxx Pharmaceuticals trades on the OTCMKTS under the ticker symbol "ELOX." How were Eloxx Pharmaceuticals' earnings last quarter? Eloxx Pharmaceuticals (OTCMKTS:ELOX) issued its quarterly earnings results on Tuesday, August, 7th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.39) by $0.03. View Eloxx Pharmaceuticals' Earnings History. What price target have analysts set for ELOX? 4 analysts have issued twelve-month target prices for Eloxx Pharmaceuticals' stock. Their forecasts range from $20.00 to $31.00. On average, they expect Eloxx Pharmaceuticals' stock price to reach $25.25 in the next twelve months. This suggests a possible upside of 58.7% from the stock's current price. View Analyst Price Targets for Eloxx Pharmaceuticals. What is the consensus analysts' recommendation for Eloxx Pharmaceuticals? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eloxx Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Eloxx Pharmaceuticals. Who are some of Eloxx Pharmaceuticals' key competitors? Some companies that are related to Eloxx Pharmaceuticals include National Research (NRCIA), Sorrento Therapeutics (SRNE), VIRALYTICS Ltd/S (VRACY), Pieris Pharmaceuticals (PIRS), HedgePath Pharmaceuticals (HPPI), Anavex Life Sciences (AVXL), Luna Innovations (LUNA), Senomyx (SNMX), Vitality Biopharma (VBIO), Dyadic International (DYAI), BIOQUAL (BIOQ), Cleveland BioLabs (CBLI), Bioanalytical Systems (BASI), Protalex (PRTX) and US Stem Cell (USRM). Who are Eloxx Pharmaceuticals' key executives? Eloxx Pharmaceuticals' management team includes the folowing people: Mr. Robert E. Ward, Chairman & CEO (Age 60)Dr. Silvia Noiman, Founder & Director (Age 62)Mr. Gregory L. Weaver CPA, M.B.A., Chief Financial Officer (Age 62)Dr. Pedro Huertas, Chief Medical Officer (Age 63)Dr. Colin Scott M.B., Ch.B., Medical Director (Age 66) Who are Eloxx Pharmaceuticals' major shareholders? Eloxx Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Menora Mivtachim Holdings LTD. (5.13%), BlackRock Inc. (3.14%), Emerald Mutual Fund Advisers Trust (0.60%), Schwab Charles Investment Management Inc. (0.33%), Northern Trust Corp (0.22%) and Bank of New York Mellon Corp (0.17%). Company insiders that own Eloxx Pharmaceuticals stock include Gilad Shabtai, Gregory L Weaver, Pontifax Management 4 GP (20, Robert Ward, Tomer Kariv and Zafrira Avnur. View Institutional Ownership Trends for Eloxx Pharmaceuticals. Which institutional investors are buying Eloxx Pharmaceuticals stock? ELOX stock was purchased by a variety of institutional investors in the last quarter, including Menora Mivtachim Holdings LTD., BlackRock Inc., Emerald Mutual Fund Advisers Trust, Schwab Charles Investment Management Inc., Northern Trust Corp, Bank of New York Mellon Corp, Bank of New York Mellon Corp and Rhumbline Advisers. Company insiders that have bought Eloxx Pharmaceuticals stock in the last two years include Gilad Shabtai, Gregory L Weaver, Pontifax Management 4 GP (20, Robert Ward, Tomer Kariv and Zafrira Avnur. View Insider Buying and Selling for Eloxx Pharmaceuticals. How do I buy shares of Eloxx Pharmaceuticals? Shares of ELOX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Eloxx Pharmaceuticals' stock price today? One share of ELOX stock can currently be purchased for approximately $15.91. How big of a company is Eloxx Pharmaceuticals? Eloxx Pharmaceuticals has a market capitalization of $313.82 million and generates $80,000.00 in revenue each year. Eloxx Pharmaceuticals employs 15 workers across the globe. What is Eloxx Pharmaceuticals' official website? The official website for Eloxx Pharmaceuticals is http://www.eloxxpharma.com. How can I contact Eloxx Pharmaceuticals? Eloxx Pharmaceuticals' mailing address is 950 WINTER STREET, WALTHAM MA, 02451. The company can be reached via phone at 858-909-0749 or via email at [email protected] MarketBeat Community Rating for Eloxx Pharmaceuticals (OTCMKTS ELOX)Community Ranking: 2.2 out of 5 ( )Outperform Votes: 74 (Vote Outperform)Underperform Votes: 95 (Vote Underperform)Total Votes: 169MarketBeat's community ratings are surveys of what our community members think about Eloxx Pharmaceuticals and other stocks. Vote "Outperform" if you believe ELOX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ELOX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 9/24/2018 by MarketBeat.com StaffFeatured Article: What is a Leveraged Buyout (LBO)?